Molecular Express, Inc. presents an innovative cleaning solution using cationic peptides with antimicrobial properties. These biodegradable peptides formulated with surfactants offer stable, effective cleansers with enhanced antimicrobial activity.
Molecular Express, Inc. introduces a groundbreaking cleaning solution incorporating cationic peptides known for their potent antimicrobial properties. These peptides are biodegradable and can be produced in large quantities. By integrating these peptides with various surfactants, the resultant formulation offers a stable and highly effective cleaning product. This innovation targets the growing demand for environmentally friendly cleaning solutions with enhanced antimicrobial efficacy.
Key features:
The formulation process involves combining the hydrophobic peptides with chosen surfactants, leading to a product that can be tailored to different cleaning applications. Standardized tests are planned to validate the antimicrobial and cleaning performance of these formulations.
This technology is currently at TRL 4, indicating that the core concept has been tested in a laboratory setting and is ready for further development and validation with industry partners.
Molecular Express, Inc. is a biotechnology company that specializes in advanced formulation services to accelerate the development of vaccines, therapeutics, and small molecule drugs. The company utilizes its proprietary Molecular GPS™ and VesiVax® platforms for targeted drug delivery, nanoparticle design, and engineering. By leveraging these advanced delivery systems, the company provides essential support for protein processing, production, and rigorous analytical testing. Its expertise enables researchers to conjugate target molecules and stabilize compounds, ensuring they meet the required quality standards for preclinical and clinical development. Molecular Express, Inc. operates as a key research and development subsidiary of Molecular GPS Technologies™, collaborating with academic institutions and government agencies to bring innovative scientific research to market.
The company plays a vital role in life sciences by helping partners secure funding and grants to translate groundbreaking discoveries into viable clinical solutions. By providing efficient, scalable protein production and customized formulation services, it addresses significant bottlenecks in therapeutic development, such as supply constraints and manufacturing complexity. Through its work with the NIH and other organizations, Molecular Express contributes to public health by developing specialized treatments, including synthetic lung surfactants and immunomodulatory adjuvants. This collaborative, research-driven approach allows the company to support a wide range of projects, from oncology and infectious disease vaccines to novel medical imaging agents and addiction therapies, ultimately bridging the gap between bench-top research and real-world medical applications.